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BACKGROUND: Arterial stiffness is an important predictor of cardiovascular events; however, indexes for measuring arterial stiff-
ness have not been widely incorporated into routine clinical practice. This study aimed to determine whether the cardio- ankle 
vascular index (CAVI), based on the blood pressure– independent stiffness parameter β and reflecting arterial stiffness from 
the origin of the ascending aorta, is a good predictor of cardiovascular events in patients with cardiovascular disease risk fac-
tors in a large prospective cohort.
METHODS AND RESULTS: This multicenter prospective cohort study, commencing in May 2013, with a 5- year follow- up period, 
included patients (aged 40‒ 74 years) with cardiovascular disease risks. The primary outcome was the composite of cardio-
vascular death, nonfatal stroke, or nonfatal myocardial infarction. Among 2932 included patients, 2001 (68.3%) were men; the 
mean (SD) age at diagnosis was 63 (8) years. During the median follow- up of 4.9 years, 82 participants experienced primary 
outcomes. The CAVI predicted the primary outcome (hazard ratio, 1.38; 95% CI, 1.16‒ 1.65; P<0.001). In terms of event sub-
types, the CAVI was associated with cardiovascular death and stroke but not with myocardial infarction. When the CAVI was 
incorporated into a model with known cardiovascular disease risks for predicting cardiovascular events, the global χ2 value 
increased from 33.8 to 45.2 (P<0.001), and the net reclassification index was 0.254 (P=0.024).
CONCLUSIONS: This large cohort study demonstrated that the CAVI predicted cardiovascular events.
REGISTRATION: URL: https://www.clini caltr ials.gov; Unique identifier: NCT01859897.
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Arterial stiffness is an important predictor of fu-ture cardiovascular events.1 Several indexes for measuring arterial stiffness, such as the carotid- 
femoral pulse- wave velocity (PWV) and the augmen-
tation index, have been proposed2– 5; however, these 
have not been widely incorporated into routine clinical 
practice. Among these indexes, the carotid- femoral 
PWV has been considered the reference standard. 
Previous studies have shown that a greater carotid- 
femoral PWV is associated with an increased risk of 
cardiovascular events in the general population and pa-
tients with hypertension or type 2 diabetes mellitus.6– 9 
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However, the use of carotid- femoral PWV has several 
limitations, such as a complex measurement proce-
dure and a bias introduced by the determination dis-
tance.10 Furthermore, because carotid- femoral PWV is 
a measure of the speed of the pulse wave, it is affected 
by blood pressure,11,12 which is an important confound-
ing factor for cardiovascular disease (CVD). Similarly, it 
remains unclear whether carotid- femoral PWV has a 
significant impact on decision making in medium- and 
high- risk individuals.
The cardio- ankle vascular index (CAVI) is a marker 
of arterial stiffness based on the stiffness parameter β, 
developed in Japan in 2004. It reflects arterial stiffness 
from the origin of the ascending aorta to the ankle.13 
The CAVI can be obtained automatically by wrapping 
pressure cuffs around the upper arms and lower legs 
and is less dependent on blood pressure.14 Several 
studies have demonstrated that the CAVI is associated 
with target organ damage, such as the presence of 
coronary artery disease (CAD) and stroke.15– 18 In ad-
dition, studies have reported the association between 
a greater CAVI and a high incidence of cardiovascu-
lar events in patients with diabetes mellitus, obesity, 
and several CVD risk factors.19– 22 Nevertheless, these 
were single- center or relatively small- scale studies, 
and some studies failed to show a significant associ-
ation between the CAVI and cardiovascular events in 
patients with metabolic syndrome or at high risk of de-
veloping CVD.23,24 Therefore, a large multicenter pro-
spective study is needed to elucidate the association 
between CAVI and cardiovascular events.
This study aimed to investigate (1) whether the CAVI 
is a good predictor of cardiovascular events in patients 
with CVD risk factors and (2) whether the CAVI offers 
incremental value for predicting future cardiovascular 
events in a large multicenter prospective cohort.
METHODS
The data that support the findings of this study are 
available from the corresponding author on reason-
able request.
Study Population
The CAVI- J (Prospective Multicenter Study to Evaluate 
Usefulness of Cardio- Ankle Vascular Index in Japan) 
was a multicenter, prospective, cohort study that 
evaluated the usefulness of the CAVI.25 This study was 
approved by the ethics committee of the Okayama 
University Graduate School of Medicine, Dentistry, and 
Pharmaceutical Sciences, as well as the ethics com-
mittees of each participating center. It was conducted 
in compliance with the Declaration of Helsinki. All par-
ticipants provided written informed consent, and this 
trial was registered at ClinicalTrials.gov (NCT01859897).
The details of the inclusion and exclusion criteria are 
described in Data S1. The eligibility criteria included 
individuals aged between 40 and 74 years and those 
who had at least one of the following risk factors for 
CVD: type 2 diabetes mellitus,26 hypertension (catego-
rized as high risk, according to the Japanese Society 
of Hypertension Guidelines for the Management of 
Hypertension 2009),27 metabolic syndrome,28 chronic 
kidney disease of stage 3,29 or a history of CAD or ce-
rebral infarction. In contrast, the exclusion criteria were 
as follows: aged <40 years or >75 years, ankle- brachial 
index ≤0.9, chronic atrial fibrillation, severe heart fail-
ure (New York Heart Association class greater than 
level III) or left ventricular dysfunction (left ventricular 
ejection fraction of <40%), medical history of cancer 
and/or treatment for cancer within the past 5  years, 
estimated glomerular filtration rate of <30 mL/min per 
1.73 m2 or receiving long- term dialysis, treatment with 
systemic steroids or immunosuppressants, or liver cir-
rhosis, and judgment of an attending physician that 
the individual was ineligible for inclusion in the study. 
Metabolic syndrome was diagnosed with the criteria 
of the Examination Committee for the Diagnosis of 
Metabolic Syndrome in Japan, 2005.28 The definition 
CLINICAL PERSPECTIVE
What Is new?
• This prospective cohort study demonstrated 
that the cardio- ankle vascular index, a marker of 
arterial stiffness based on the stiffness param-
eter β, predicted cardiovascular events in pa-
tients with cardiovascular disease risk factors.
• In terms of event subtypes, the cardio- ankle 
vascular index was associated with the risk of 
cardiovascular death, nonfatal stroke, all- cause 
mortality, and heart failure with hospitalization.
What Are the Clinical Implications?
• The cardio- ankle vascular index may be clini-
cally useful for assessing the risk of cardiovas-
cular events among patients with risk factors for 
cardiovascular disease.
• Our findings warrant the need for future studies 
to verify our results, compare the cardio- ankle 
vascular index with other arterial stiffness mark-
ers, and estimate the threshold for each cardio-
vascular event.
Nonstandard Abbreviations and Acronyms
CAVI cardio- ankle vascular index
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of metabolic syndrome was abdominal obesity with a 
waist circumference ≥85 cm for men and ≥90 cm for 
women and ≥2 of the following 3 risk factors: (1) high 
blood pressure (systolic blood pressure ≥130 mm Hg 
and/or diastolic blood pressure ≥85 mm Hg or treat-
ment for previously diagnosed hypertension), (2) hyper-
glycemia (fasting glucose level ≥110 mg/dL or treatment 
for previously diagnosed type 2 diabetes mellitus), and 
(3) dyslipidemia (triglyceride levels ≥150 mg/dL and/or 
high- density lipoprotein [HDL] cholesterol <40 mg/dL 
or treatment for previously diagnosed dyslipidemia).
In total, 3026 patients were enrolled between May 
2013 and December 2014. The participants were fol-
lowed up prospectively for 5 years from the date of de-
termining the CAVI. Participants’ status was checked 
from medical records in their corresponding hospitals 
or clinics and by mail or telephone for any participants 
who had moved during the follow- up. Participants were 
managed by their attending physicians, who were en-
couraged to treat CVD risk factors, including hyper-
tension, dyslipidemia, and diabetes mellitus, to achieve 
the best available standard of care in accordance with 
the relevant guidelines.
Primary Exposure
The primary exposure was the baseline CAVI, meas-
ured with a VaSera device (Fukuda Denshi, Tokyo, 
Japan). The CAVI was determined using the following 
formula: CAVI=a {(2ρ/∆P)×ln (Ps/Pd) PWV2}+b, where 
a and b are constants applied according to the value 
derived from the equation: (2ρ/∆P)×ln (Ps/Pd) PWV2 (a 
and b: 0.850 and 0.695, 0.658 and 2.103, and 0.432 
and 4.441, respectively),30 ρ is blood density (the fixed 
value of 1.05 is used), ΔP is Ps– Pd, Ps is systolic blood 
pressure, Pd is diastolic blood pressure, and PWV is 
the pulse- wave velocity. The details of the measure-
ment have been described previously.13 ECG elec-
trodes were placed on both wrists, a microphone 
was placed on the sternum to detect heart sounds, 
and cuffs were applied to the upper arms and ankles, 
bilaterally, with the patient in the supine position. To 
detect the brachial and ankle pulse waves with cuffs, 
a low cuff pressure of 30 to 50 mm Hg was used to 
minimize the effect of cuff pressure on hemodynam-
ics. Thereafter, blood pressure was measured from the 
cuff on the upper arm. PWV was obtained by dividing 
the vascular length by the time taken for the pulse wave 
to propagate from the aortic valve to the ankle; it was 
measured using cuffs at the upper arms and ankles. 
Intraobserver and interobserver variability have been 
reported to be <3.8% and 2.4%, respectively.13,17,31– 33 
To ensure the quality of the measurement, 2 conditions 
were established. First, qualified hospitals or clinics, 
based on the past performance of the CAVI measure-
ment, could participate in this study. Second, all raw 
data of CAVI were sent for evaluation at the central 
office. Subsequently, remeasurement was required in 
case of inappropriate data.
Outcomes
The primary outcome was the composite cardiovascu-
lar events of cardiovascular death, myocardial infarc-
tion, and stroke. Stroke included ischemic stroke and 
hemorrhagic stroke. In contrast, secondary outcomes 
were all- cause death, stable angina pectoris with re-
vascularization, the new incidence of peripheral arte-
rial disease, aortic aneurysm, aortic dissection, heart 
failure with hospitalization, and deterioration in renal 
function. The details of definitions are provided in Data 
S1. All events were reported annually by each institu-
tion to the Clinical Endpoint Review Committee. The 
committee, consisting of members blinded to informa-
tion about the patients, assessed the appropriateness 
of the clinical judgment of all events according to pre-
specified criteria.
Covariates
A self- administered questionnaire on smoking habits 
and physical activity was checked by trained interview-
ers. These variables were classified as being either 
habitual or not. The use of medications was similarly 
checked. Blood pressure was measured twice using 
an automated sphygmomanometer with participants in 
the sitting position after a 5- minute rest. The mean of 
the 2 measurements was used for the present analy-
sis. Serum total and HDL cholesterol concentrations 
were determined enzymatically. Obesity was defined 
as a body mass index >30.0 kg/m2, and all clinical ex-
aminations and blood tests were conducted on the 
same day.
Statistical Analysis
The sample size was calculated as follows: The rela-
tive risk of cerebrovascular events in patients with a 
CAVI >10 has been estimated to be 1.73, compared 
with patients with a CAVI ≤10; thus, the study en-
rolled 2.5 times as many patients with a CAVI ≤10 
as patients with a CAVI >10,34 in whom the risk of 
cerebrovascular events is anticipated to be 4.6% in 
5 years.35 From these data, the risks of cerebrovascu-
lar events in patients with a CAVI ≤10 and those with 
a CAVI >10 were anticipated to be 0.038 and 0.066 in 
5 years, respectively. To detect this difference in risk, 
the required sample size was calculated, using the 
Freedman method, to be 810 for those with a CAVI 
≤10 and 2024 for those with a CAVI >10, with a 5% 
2- sided α value, 80% power, and 20% dropout rate. 
On the basis of these assumptions, a sample size of 
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Categorical data are presented as absolute num-
bers and percentages. Continuous data are pre-
sented as mean (SD). Baseline characteristics were 
compared according to the CAVI quintile (quintile 1, 
≤7.55; quintile 2, 7.60‒ 8.20; quintile 3, 8.25‒ 8.80; 
quintile 4, 8.85‒ 9.45; and quintile 5, ≥9.50). The lin-
ear trends in the mean values and the frequencies 
of risk factors across the CAVI levels were tested 
using linear regression analysis and logistic regres-
sion analysis, respectively. Cumulative event rates 
were estimated by the Kaplan- Meier method for the 
primary outcome, and a log- rank test was used to 
compare groups. Cox proportional hazards regres-
sion analysis was performed to investigate the as-
sociation between clinical outcomes and the CAVI 
value. Proportional hazard assumption was evalu-
ated on the basis of the log- log plot. Annualized inci-
dence rates were calculated per 1000 patient- years 
of follow- up. The hazard ratios (HRs) and 95% CIs 
were calculated and reported. The incremental value 
of the CAVI for predicting cardiovascular events was 
assessed using the Akaike information criterion and 
the global χ2 test. To assess the discrimination of 
events, receiver- operating characteristic curve anal-
ysis was performed. Similarly, we calculated the 
continuous net reclassification improvement and 
integrated discrimination improvement. A 2- tailed 
P<0.05 was considered statistically significant. 
Statistical analyses were performed using SPSS for 
Windows, version 25.0 (IBM Corporation, Tokyo, 




The median (interquartile range) follow- up period was 
4.9 (4.6‒ 5.2) years. In total, 94 patients were excluded 
because 60 patients had no follow- up data, and 34 
withdrew consent. Finally, 2938 patients (2001 men 
and 937 women; mean [SD] age, 63.2 [8.0] years) 
were included in the analysis. The baseline charac-
teristics of the patients are shown in Table S1. The 
baseline characteristics of patients included in the 
analysis according to the CAVI quintiles are shown in 
Table 1. Baseline Characteristics According to the CAVI
Characteristics
CAVI











(N=579) (N=578) (N=614) (N=577) (N=584)
Age, mean (SD), y 57.2 (9.3) 61.7 (7.9) 64.0 (7.0) 65.6 (6.2) 67.3 (5.2) <0.001
Men 342 (59.1) 375 (64.9) 414 (67.4) 422 (73.1) 448 (76.7) <0.001
Systolic blood pressure, mean (SD), mm Hg 130.5 (15.4) 131.3 (16.3) 132.0 (15.7) 134.8 (17.3) 137.3 (16.9) <0.001
Diastolic blood pressure, mean (SD), mm Hg 80.2 (11.0) 79.9 (11.8) 78.9 (10.8) 80.4 (11.5) 80.5 (12.1) 0.089
Hypertension 499 (86.2) 512 (88.6) 533 (86.8) 513 (88.9) 540 (90.5) 0.002
Hypertension (high risk) 458 (79.1) 477 (82.5) 484 (78.8) 490 (84.9) 522 (89.4) <0.001
Diabetes mellitus 430 (74.3) 416 (72.0) 458 (74.6) 438 (75.9) 467 (80.0) 0.007
Metabolic syndrome 183 (31.6) 150 (26.0) 172 (28.0) 161 (27.9) 154 (26.4) 0.148
Chronic kidney disease 198 (34.2) 219 (37.9) 222 (36.2) 233 (40.4) 253 (43.3) 0.001
History of coronary artery disease or cerebral 
infarction
197 (34.0) 216 (34.4) 231 (37.6) 224 (38.8) 247 (42.3) 0.005
Total cholesterol, mean (SD), mg/dL 188.4 (34.5) 184.0 (34.7) 183.9 (33.4) 182.6 (35.5) 180.3 (34.4) 0.002
HDL cholesterol, mean (SD), mg/dL 55.4 (15.1) 54.9 (16.0) 55.7 (15.5) 54.8 (15.5) 53.9 (14.7) 0.344
Obesity 163 (28.2) 69 (11.9) 54 (8.8) 43 (7.5) 30 (5.1) <0.001
Smoking habits 246 (42.5) 244 (42.2) 279 (45.4) 277 (48.0) 264 (45.2) 0.086
Regular exercise 195 (33.7) 193 (33.4) 212 (34.5) 217 (37.6) 209 (35.8) 0.179
Medications
Antihypertensive agents 443 (76.5) 454 (78.6) 473 (77.0) 427 (74.0) 463 (79.3) 0.850
Insulin 22 (3.8) 31 (5.4) 32 (5.2) 32 (5.6) 57 (9.8) <0.001
Antidiabetic agents 179 (30.9) 189 (32.7) 22 (37.8) 237 (41.1) 272 (46.6) <0.001
Lipid- lowering agents 345 (59.6) 372 (64.4) 376 (61.2) 334 (57.9) 378 (64.7) 0.545
Antiplatelet agents 190 (32.8) 213 (36.9) 229 (37.3) 214 (37.1) 246 (42.1) 0.003
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Table 1. Patients with higher CAVI levels were older 
and were more likely to be men. The mean systolic 
blood pressure, prevalence of hypertension, diabetes 
mellitus, and obesity, use of insulin, and the use of 
antidiabetic as well as of antiplatelet agents increased 
significantly with a higher CAVI. The mean diastolic 
pressure and HDL cholesterol values, the prevalence 
of chronic kidney disease, history of CAD or cerebral 
infarction, smoking habits, regular exercise, and use 
of lipid- lowering agents did not differ among the CAVI 
quintile groups.
Association Between the CAVI and 
Primary Outcomes
During the follow- up, 82 participants experienced primary 
outcomes. These included 13 cardiovascular deaths, 44 
nonfatal stroke cases, and 25 nonfatal myocardial infarc-
tion cases. The cumulative incidence rates of the primary 
outcomes are shown according to the CAVI levels in the 
Figure 1, and the rates were significantly higher in the fifth 
quintile group than in the first quintile group (P value for 
trend=0.01). Risk factors for cardiovascular events ana-
lyzed in the univariate Cox proportional hazard models are 
shown in Table S2. Male sex, HDL cholesterol, smoking 
habits, alcohol intake, and use of antiplatelet agents, but 
not systolic or diastolic blood pressure, were associated 
with cardiovascular events. The age- and sex- adjusted 
HRs increased linearly with elevating CAVI levels, and this 
relationship remained significant after adjusting for age, 
male sex, systolic blood pressure, type 2 diabetes melli-
tus, HDL cholesterol, smoking, history of CAD or cerebral 
infarction, and use of antihypertensive agents (Table 2). In 
the multivariable- adjusted model, the fifth quintile of CAVI 
(≥9.50) was associated with increased risk of the pri-
mary outcomes compared with the first quintile of CAVI 
(≤7.55), after adjusting for the above confounding factors 
(HR, 3.31 [95% CI, 1.26‒ 8.71]; P=0.016). Every 1- point 
increment in the CAVI was similarly associated with an 
increased risk of the primary outcomes, after adjusting 
for the confounding factors (HR, 1.38 [95% CI, 1.16‒ 1.65]; 
P<0.001).
Figure. Kaplan- Meier plot of cumulative probability of cardiovascular events by quintiles of the 
cardio- ankle vascular index (CAVI).
Time to cardiovascular events, including cardiovascular death, nonfatal stroke, and nonfatal myocardial 
infarction, according to baseline CAVI. The cumulative incidence rates of the primary outcomes according 
to the CAVI levels were significantly higher in the fifth quintile group (CAVI ≥9.50) than in the first quintile 
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Association Between the CAVI and Each 
End Point
Subsequently, the association between the CAVI and 
each end point was assessed. After evaluating the 
proportional hazard assumption, the associations of 
the CAVI with cardiovascular death, nonfatal stroke, 
nonfatal myocardial infarction, and heart failure with 
hospitalization were analyzed in the Cox proportional 
hazard models (Table 3). On the basis of the events 
included in the primary outcome, a CAVI >9.5 was 
significantly associated with the risk of cardiovascu-
lar death and nonfatal stroke (crude HR, 3.83 [95% 
CI, 1.28‒ 11.40]; P=0.015; and crude HR, 2.07 [95% 
CI, 1.07‒ 3.91]; P=0.024, respectively), but not with 
nonfatal myocardial infarction, as a CAVI ≤9.5 was 
considered as the reference. For the events included 
in the secondary outcome, a CAVI >9.5 was sig-
nificantly associated with the incidence of all- cause 
mortality and heart failure with hospitalization (crude 
HR, 1.90 [95% CI, 1.11‒ 3.26]; P=0.018; and crude 
HR, 3.38 [95% CI, 1.42‒ 8.01]; P=0.005, respectively).
Estimation of the Risk Assessment Ability 
for Cardiovascular Events
To determine the incremental value of the CAVI for pre-
dicting cardiovascular events, the Akaike information cri-
terion test, a likelihood ratio test, and receiver- operating 
characteristic curve analysis were performed (Table 4). 
The baseline model comprised the following param-
eters: age, male sex, systolic blood pressure, type 2 
diabetes mellitus, HDL cholesterol, smoking, history of 
CAD or cerebral infarction, and use of antihypertensive 
agents. The addition of the CAVI to the baseline model 
improved the model fit, as indicated by a reduction in the 
Akaike information criterion from 731.3 to 721.9, and sig-
nificantly increased the global χ2 value from 33.8 to 45.2 
(P<0.001). The increase in C- statistic was not significant 
(0.688 to 0.708; P=0.146). Addition of the CAVI yielded a 
category- free net reclassification index of 0.254 (95% CI, 
0.034‒ 0.472; P=0.024) and an integrated discrimination 
improvement of 0.006 (95% CI, 0.000‒ 0.012; P=0.052).
DISCUSSION
We found that the CAVI was a predictor of the onset 
of cardiovascular events in patients with CVD risk fac-
tors. The analysis of the CAVI and different outcomes 
showed that CAVI was associated with incidence of 
cardiovascular death, nonfatal stroke, all- cause mor-
tality, and heart failure with hospitalization. To our 
knowledge, all previous studies that have investigated 
the relationship between the CAVI and the incidence 
of cardiovascular events were smaller, single- center 
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significant association between the CAVI and the risk 
of cardiovascular events.23,24 Therefore, the study find-
ings highlight the clinical usefulness of the CAVI in the 
risk assessment of cardiovascular events among pa-
tients at risk of cardiovascular events.
There have been several single- center, small- scale 
studies on the CAVI and the incidence of cardiovas-
cular events.15,20– 24 A study, including 400 patients 
with hypertension, diabetes mellitus, or dyslipidemia, 
showed that patients with a CAVI ≥10.0 had a 1.73 rel-
ative risk of elevated cerebrovascular events compared 
with those with a CAVI <9.0.34 A study including 626 
patients with type 2 diabetes mellitus showed that a 
CAVI ≥9.0 was associated with increased cardiovas-
cular events, compared with a CAVI <9.0 (HR, 1.23; 
95% CI, 1.07‒ 1.42).22 A study including 425 obese pa-
tients showed that the CAVI was a significant factor for 
the incidence of cardiovascular events (HR, 1.44 per 
1- point increase in the CAVI; 95% CI, 1.02‒ 2.02).20 In 
a study including 1562 patients with CVD risk factors, 
the CAVI was significantly associated with cardiovas-
cular events (HR, 1.13 per 1- point increase in the CAVI; 
95% CI, 1.01‒ 1.26).21 In the present study, a CAVI ≥9.50 
was shown to be significantly associated with the in-
creased incidence of cardiovascular events compared 
with CAVI ≤7.55. This finding was consistent with those 
of previous studies. However, there are several differ-
ences between the present study and the previous 
studies. First, this study was a multicenter, large- scale 
cohort. Second, this study included heterogeneous 
patients with several CVD risk factors and preexisting 
CVD. Thus, the present study demonstrated that CAVI 
is useful in the assessment of the risk for future cardio-
vascular events in patients with CVD risk factors.
In our study, CAVI was associated with the risk of 
nonfatal stroke, but not with that of nonfatal myocar-
dial infarction. However, previous studies have shown 
that an increase in carotid- femoral PWV is associated 
with a greater risk of CAD rather than of stroke.8,9 
There are several explanations for the discrepancy. 
First, the definition of CAD in most previous studies 
was the composite outcome, including the incidence 
of acute coronary syndrome and the revascularization 
for chronic coronary syndrome. There were a few data 
about the impact of arterial stiffness on different end 
points. The substudy of the SPRINT (Systolic Blood 
Pressure Intervention Trial) showed that the estimated 
PWV was not associated with the incidence of myo-
cardial infarction and acute coronary syndrome, which 
is consistent with our findings.36 Second, longitudinal 
cohort studies in Asian populations have shown that 
an increase in brachial- ankle PWV was associated with 
a greater incidence of stroke than of CAD.37,38 Several 
hypotheses underlying the association between arterial 
stiffness and atherosclerosis have been proposed. The 
arterial systolic pressure increases, and the diastolic 
pressure decreases, in the stiffened artery. Increased 
luminal pressure and shear stress accelerate the for-
mation of atheroma and stimulate excessive collagen 
production and deposition in the arterial wall, leading 
to the progression of atherosclerosis.39 In addition, in-
creased pulse pressure may be associated with the 
development of plaque and its subsequent rupture.40 
Further clinical investigation will be needed to evalu-
ate the clinical relevance of CAVI in the development of 
acute coronary syndrome.
This study demonstrated that increased CAVI was 
associated with heart failure with hospitalization. Heart 
Table 3. Association of CAVI >9.5 With Each End Point
End Point No. (%) of Events Crude HR (95% CI) P Value
Cardiovascular death 13 (0.4) 3.83 (1.28– 11.4) 0.015
Nonfatal stroke 44 (1.5) 2.07 (1.10– 3.91) 0.024
Nonfatal myocardial infarction 25 (0.8) 1.13 (0.42– 3.02) 0.080
All- cause mortality 64 (2.2) 1.90 (1.11– 3.26) 0.018
Heart failure with hospitalization 21 (0.7) 3.38 (1.42– 8.01) 0.005
CAVI indicates cardio- ankle vascular index; and HR, hazard ratio.
Table 4. Incremental Prognostic Value of the CAVI for Cardiovascular Events After Addition to a Model Incorporating 
Known Risk Factors
Model AIC Global χ2 score C- Statistic NRI (95% CI) IDI (95% CI)
P Value P Value P Value P Value
Age, sex, and risk factors* 731.3 33.8 0.688
With CAVI added 721.9 45.2 <0.001 0.708 0.146 0.254  
(0.034– 0.472)
0.024 0.006  
(0.000– 0.012)
0.052
AIC indicates Akaike information criterion; CAVI, cardio- ankle vascular index; IDI, integrated discrimination improvement; and NRI, net reclassification index.
*Risk factors included age, male sex, systolic blood pressure, diabetes mellitus, high- density lipoprotein cholesterol, smoking, history of coronary artery 
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failure is a growing public health problem worldwide 
because of its high mortality and morbidity.41,42 The 
mechanisms underlying acute heart failure are manifold 
because this disease results from a complex of struc-
tural and functional alterations. Among them, increased 
arterial stiffness has been proposed as a potential and 
important noncardiac factor in the pathogenesis of heart 
failure.43,44 Stiff aorta increases the systolic afterload 
and worsens ventricular- vascular coupling.45 Although 
further investigations are needed, the measurements of 
CAVI might be helpful in identifying patients at increased 
risk for heart failure with hospitalization.
In the present study, the CAVI only mildly improved 
cardiovascular event discrimination over that by known 
risk factors. A recent meta- analysis of the association 
between brachial- ankle PWV and cardiovascular events 
demonstrated that the significant incremental prognostic 
value of brachial- ankle PWV for predicting cardiovascu-
lar events over that of the Framingham risk score was 
attenuated in participants with intermediate or high risk. 
This study included heterogeneous patients with several 
CVD risk factors and preexisting CVD, who had relatively 
moderate to high risks of cardiovascular events; this may 
explain the mild effect of the CAVI in the discrimination 
of cardiovascular events in this study. Further analyses, 
according to the magnitude of risks, will be needed.
There have been several techniques and methods 
applied to quantify arterial stiffness. A study demon-
strated that CAVI was significantly correlated with 
carotid- femoral PWV and brachial- ankle PWV (Pearson 
correlation coefficients, 0.74 and 0.82, respectively).46 
However, there are notable differences among arterial 
stiffness measurements. Carotid- femoral PWV is ob-
tained by applanation tonometry, which is a complicated 
technique compared with CAVI and brachial- ankle PWV. 
CAVI and brachial- ankle PWV are derived from pleth-
ysmography cuff automatically.25 Meanwhile, CAVI is a 
noninvasive indicator of arterial stiffness. It has an ad-
vantage over PWV for measuring arterial stiffness as 
it is less dependent on blood pressure at the time of 
measurement.14 An assessment of arterial properties by 
considering blood pressure and arterial stiffness may 
allow detailed monitoring of changes in arterial stiffness 
in daily practice. Furthermore, the CAVI measurement is 
simple. The CAVI is easily obtained automatically with a 
device, leading to its widespread use in clinical situations 
if cost constraints are ignored. Further investigations will 
be needed to elucidate this matter, with due consider-
ation given to cost- effectiveness.
The measurement of CAVI has been included in the 
routine clinical setting in Japan. CAVI is measured for 
the risk stratification in patients with atherosclerotic risk 
factors and for the evaluation of therapeutic efficacy of 
medications and lifestyle modification in patients with 
cardiometabolic disorders on a regular basis. In addition, 
the VaSera device can evaluate the ankle- brachial index 
simultaneously, which helps to diagnose peripheral arte-
rial disease. The measurement of CAVI has been covered 
by health insurance in Japan, and, thus, the measure-
ment of CAVI is applied widely in clinical practice.
This study had several limitations. First, as this 
was an observational cohort study, a causal relation-
ship between an increased CAVI and increased car-
diovascular events could not be proved. Second, the 
study population comprised only Japanese patients. 
Although several studies of non- Asian populations 
have recently been reported,47,48 the generalizability of 
our data to other races/ethnicities remains uncertain. 
Third, the present study examined arterial stiffness 
only by the CAVI. Therefore, we could not compare 
the impact of the CAVI with those of other stiffness 
markers. Finally, we failed to estimate a threshold for 
each event because of the modest number of events. 
Hence, a further study with longer follow- up or a larger 
sample is warranted.
In conclusion, our findings demonstrated that, in 
patients with CVD risk factors, patients with a higher 
CAVI (≥9.50) have elevated risks of cardiovascular 
events. These data suggest that the CAVI is clinically 
useful in the assessment of the risk of cardiovascular 
events among patients with CVD risk factors.
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1. STUDY SYNOPSIS
Title Protocol for evaluating the cardio–ankle vascular index to predict cardiovascular events in Japan: 
A prospective multicenter cohort study (CAVI-J) 
Coordinating Center 2-5-1 Shikata-cho, Okayama, Okayama University
Study Chair Hajime Orimo, MD 
Overall Objective An open label, international, multicenter observational registry designed to examine the benefits 
of cardio–ankle vascular index (CAVI) as a predictor of cardiovascular events in high-risk patients. 
Study Design A multicenter observational registry. The study will be conducted in up to 50 sites in Japan. 
Study Cohorts A total of 3,000 subjects undergoing CAVI will be enrolled. 
Eligibility Inclusion Criteria: 
1. Adult individual between 40 and 74 years of age
2. Type 2 diabetes mellitus
3. Metabolic syndrome
4. Hypertension categorized as high-risk
5. Chronic kidney disease (stage 3)
6. History of coronary artery disease or cerebral infarction
Exclusion Criteria: 
1.Under 40 years of age or over 75 years of age
2.Ankle brachial index < 0.9
3.Chronic atrial fibrillation
4.Heart failure (NYHA class III or IV) or left ventricular dysfunction (EF below 40%)
5.Medical history of cancer and/or treatment for cancer within the last 5 years
6.Estimated glomerular filtration rate <30 ml/min/1.73m2
7.Chronic hemodialysis
8.Treatment with systemic steroids or immunosuppressants
9.Liver cirrhosis
10.History of PCI/CABG within 6months
11.Severe valvular stenosis or regurgitation
12.Determined as unsuitable for this study by a physician
Duration of Study Accrual is expected to take 6 years. All subjects enrolled will be followed-up for 5 years. Total 
duration of the study will be 6 years. 
Primary Endpoint 1. Cardiovascular death
2. Nonfatal myocardial infarction
3. Nonfatal stroke
Secondary Endpoint 1. All cause death
2. Stable angina pectoris with revascularization
3. New incidence of peripheral arterial disease (arteriosclerosis obliterans)
4. Aortic aneurysm
5. Aortic dissection
6. Heart failure with hospitalization
7. Deterioration in renal function (chronic dialysis or kidney transplantation)
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2. BACKGROUND AND RATIONALE
Atherosclerosis is a major contributor to the development of cardiovascular diseases and thus a major cause of 
mortality and morbidity [1]. Reflecting the aging of society and adoption of westernized lifestyles, the number of 
patients with cardiovascular diseases is also increasing [2]. Risk factors for cardiovascular disease consist of 
male sex, advanced age, hypertension, diabetes mellitus, dyslipidemia, obesity, and smoking. Patients often 
have several risk factors [3]; these need to be carefully managed to prevent future cardiovascular events. The 
availability of a simple and noninvasive indicator for monitoring would be a powerful tool for managing 
atherosclerotic risk factors. 
The cardio-ankle vascular index (CAVI) was developed in Japan and is a blood pressure-independent index 
of arterial stiffness from the origin of the aorta to the ankle [4]. In recent years, it has been studied by many 
researchers worldwide and it is strongly anticipated that it will play a role as a predictive factor for arteriosclerotic 
diseases. Published studies have shown that CAVI increases in the presence of cerebrovascular disease [5], 
dementia [6], cardiovascular disease [7-9], nephrosclerosis [10], vasculitis [11, 12], hypertension [13], 
hyperlipidemia [10], and lifestyle-related diseases including diabetes mellitus [14], smoking [15], sleep apnea 
syndrome [16], stress [17] and obesity [18], all of which are considered risk factors for arteriosclerosis. Recently, 
a single center study reported a positive association between high CAVI values and incidence of cardiovascular 
diseases [19]. However, no long-term multicenter prospective studies of this association have yet been reported. 
3. STUDY DESIGN
CAVI-J is a prospective multicenter cohort study with central registration in Japan. The targeted population is 
heterogeneous, given the clinical use of CAVI across a number of indications. As such, patients referred for 
clinically indicated CAVI and meet the inclusion and the exclusion criteria will include those undergoing evaluation 
for atherosclerotic diseases. The study is considered non-significant risk because: 1) CAVI is a non- invasive 
diagnostic modality; 2) this is an observational registry with no targeted downstream alteration to the clinical care 
pathway of the patient or additional interventions. Up to 50 medical centers from Japan will participate in the study, 
3,000 subjects will be enrolled into the study. Each Center may not enroll more than 20% of the total number of 
subjects. 
4. STUDY OBJECTIVES
Primary Objective. To examine the benefits of CAVI as a predictor of primary endpoints (cardiovascular death, 
nonfatal myocardial infarction, and non-fatal stroke). 
Secondary Objectives.  The secondary objectives of CAVI-J include: 
1) To determine the clinical implication of CAVI in each cardiovascular event, including
a) Primary endpoints: cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke
b) Secondary endpoints: all cause death, stable angina pectoris with revascularization, new incidence of
peripheral arterial disease (arteriosclerosis obliterans), aortic aneurysm, aortic dissection, heart failure with 
hospitalization, Deterioration in renal function (dialysis or renal transplantation) 
2) To determine the clinical implication of CAVI in different patient subgroups, including:
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b) Metabolic syndrome
c) Hypertension categorized as highest-risk
d) Chronic kidney disease (stage 3)





j) Medication at baseline
3) To examine the association of change in CAVI over time and cardiovascular events
5. STUDY ENDPOINTS
Primary Endpoint (Definition of each event is defined in Appendix file.) 
1. Cardiovascular death
2. Nonfatal myocardial infarction
3. Nonfatal stroke
Secondary Endpoint (Definition of each event is defined in Appendix file.) 
1. All cause death
2. Angina pectoris with revascularization
3. New incidence of peripheral arterial disease (arteriosclerosis obliterans)
4. Aortic aneurysm
5. Aortic dissection
6. Heart failure with hospitalization
7. Deterioration in renal function (dialysis or renal kidney transplantation)
6. PATIENT POPULATION
This study will prospectively enrol 3,000 patients undergoing CAVI. Sites participating in the CAVI-J of the study 
will be selected based on data quality and quantity of CAVI. 
7. ELIGIBILITY
Patient Eligibility and Screening.  
Patients who have presented or are presenting at a clinic or a hospital for clinical indication — and who meet the 
inclusion criteria and none of the exclusion criteria — will be included into CAVI-J study. 
Enrollment. 
3,000 subjects will be enrolled, with no more than 20% of the total study population enrolled per site. 
Consecutive consenting adult patients who meet the inclusion criteria and none of the exclusion criteria will be 
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Ethical Considerations. 
The study will be approved by the ethics committees of all hospitals involved. All participants provided written 
informed consent before enrollment. This study is conducted according to the principles expressed in the 
Declaration of Helsinki and is registered at ClinicalTrials.gov (NCT01859897). 
Informed Consent 
Study-specific data collection cannot be started until the patient has met all clinical inclusion criteria and written 
informed consent has been obtained. The investigator, or a person designated by the investigator who has been 
trained on the Investigational Plan, will explain the nature and scope of the study, potential risks and benefits of 
participation, and answer questions from the patient. If the patient agrees to participate, the informed consent form 
must be signed and personally dated prior to enrollment by the patient or his/her legally authorized representative 
and the investigator or a person designated by the investigator. A copy of the fully executed informed consent form 
must be provided to the patient. All patients must provide written informed consent in accordance with the ethics 
committee. 
Inclusion Criteria: 
patients between 40 and 74 years of age who have at least one of the following 
1.Type 2 diabetes mellitus
2.Metabolic syndrome
3.Hypertension categorized as high-risk c)
4.Chronic kidney disease (stage 3) d)
5.History of coronary artery disease or cerebral infarction e) 
Exclusion Criteria: 
1.Under 40 years of age or over 75 years of age
2.Ankle brachial index < 0.9
3.Chronic atrial fibrillation
4.Heart failure (NYHA class III or IV) or left ventricular dysfunction (EF below 40%)
5.Medical history of cancer and/or treatment for cancer within the last 5 years
6.Estimated glomerular filtration rate <30 ml/min/1.73m2
7.Chronic hemodialysis
8.Treatment with systemic steroids or immunosuppressants
9.Liver cirrhosis
10.History of PCI/CABG within 6months
11.Severe valvular stenosis or regurgitation
12.Determined as unsuitable for this study by a physician
Definition of inclusion criteria 
Type 2 diabetes mellitus: Diabetes mellitus was defined according to the American Diabetes Association. [20] 
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Committee on the Diagnosis and Classification of Metabolic Syndrome for the clinical diagnosis of metabolic 
syndrome. [8] Waist circumference > 85cm (men) or > 90cm and at least two of following additional risks: fasting 
glucose > 110mg/dL, triglyceride > 150 mg/dL or HDL < 40mg/dL, and systolic blood pressure > 130mmHg or 
diastolic blood pressure > 85mmHg. 
Hypertension categorized as high-risk: Hypertension categorized as high-risk was defined as a complication of 
diabetes mellitus or chronic kidney disease, or organ damages or multiple risk factors according to the guidelines 
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Chronic kidney disease (stage 3): Chronic kidney disease (stage 3) was defined as including patients with 
estimated glomerular filtration rates from 30 to 60 mL/min/1.73 m2 in accordance with clinical practice guidebook 
for diagnosis and treatment of chronic kidney disease 2012 [22] 
History of coronary artery disease or cerebral infarction: History of coronary artery disease was defined as 
condition over 6 months after percutaneous coronary intervention or coronary artery bypass surgery. Coronary 
artery disease included angina pectoris, myocardial infarction, and unstable angina. Non-cardiogenic cerebral 
infarction is defined as cerebral infarction with an evidence by imaging modality (CT and MRI) except for 
cardioembolic infarction and intracerebral hemorrhage.  
Patient Discontinuation 
Every subject should remain in the study until completion of the required study period. However, a subject’s 
participation in any Clinical Investigation is voluntary and the subject has the right to withdraw at any time 
without penalty or loss of benefit. 
8. STUDY DURATION
The anticipated duration of this study will be 6 years. Qualifying patients will be enrolled in the study for the first 1 
years, and followed for an additional 5 years through follow up visits and/or phone calls. 
Activity Start Day Finish Day Comments 
Site activation June 2013 
Subject enrollment June 2013 December 2014 
Data monitoring June 2013 May 2019 Simultaneous with 
enrollment and follow up 
Data analysis December 2019 --- 
Abstracts / Publications February 2020 --- 
9. DATA COLLECTION
The following data will be collected:
Enrollment/Baseline Year 1-5 
Inclusion and Exclusion Criteria x 
CAVI x x** 
Clinical Presentation x 
Demographics x 
CAD Risk Factors x 
Other Medical Conditions x 
Height and Weight x 
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Drinking habit/physical activity x 
Primary and secondary outcomes x x 
* Laboratory test must be performed at same date of CAVI. ** Annual measurement of CAVI is not mandatory.
10. STUDY-SPECIFIC VARIABLES
Data dictionaries and case report forms will be provided to study investigators. These will include: 
Baseline Data and Laboratory Assessments  
Laboratory assessment and collection will be in accordance with standard hospital policy. In addition, the following 







• Urine protein (semi-quantitative)
Electrocardiogram 









History of CAD: 
• Myocardial infarction
• Percutaneous coronary intervention
• Coronary artery bypass graft
History of ischemic stroke 
Concomitant medications: 
• Lipid-lowering agents – statins, ezetimibe, omega-3 fatty acid, etc.
• Antiplatelet therapy – aspirin, P2Y12-inhibitors
• Oral anti-coagulants – warfarin, DOACs
• Anti-hypertensive agents
• Diabetic agents – metformin, SGLT2 inhibitor, insulin, etc.
• Anti-osteoporosis agents
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• Peripheral arterial disease
• Sleep apnea syndrome
• Chronic kidney disease
• Family history of diabetes, hypertension, and cardiovascular diseases
Drinking habits: how many times per week, how much volume per once converted as alcohol 
Physical activity: 
Moderate physical activity (>150 minutes per week), vigorous physical activity (> 75 minutes per week) or no 
physical activity (< 75 minutes per week) will be recorded [23]. 
CAVI measurements: 
CAVI was measured using a CAVI device (Vasera; Fukuda Denshi, Tokyo, Japan). Electrocardiogram electrodes 
were placed on both wrists, a microphone for detecting heart sounds was placed on the sternum, and cuffs were 
applied to the upper arms and ankles bilaterally with the patient lying supine and the head held in the midline 
position. The examinations were performed after resting for 10 minutes. The pressure of all cuffs was kept low at 
50 mmHg to minimize the effect of cuff pressure on hemodynamics. Blood pressure was then measured. Pulse 
wave velocity (PWV) was to be obtained by dividing vascular length by the time (T) taken for the pulse wave to 
travel from the aortic valve to the ankle. However, in practice T was difficult to obtain because the time the blood 
left the aortic valve was difficult to identify from the sound of the valve opening. Thus, because the time between 
the sound of the aortic valve closing and the notch of the brachial pulse wave is theoretically equal to the time 
between the sound of the aortic valve opening and the rise of the brachial pulse wave, T was obtained by adding 
the time between the sound of the aortic valve closing and the notch of the brachial pulse wave and the time 
between the rise of the brachial pulse wave and rise of the ankle pulse wave. CAVI was determined using the 
following formula: CAVI=a{(2ρ/∆P)×ln(Ps/Pd)PWV2}+b, where a and b are constants, ρ is blood density, ∆P is Ps–
Pd, Ps is systolic blood pressure, and Pd is diastolic blood pressure.  
11. DATA HANDLING AND RECORD KEEPING
The CAVI-J office will perform data management activities including documentation of the systems and procedures 
to be used. All e case report form (CRF) data collection will be performed through a secure web portal and all 
authorized personnel with access to the electronic data capture (EDC) system must use an electronic signature 
access method to enter, review or correct data. Passwords and electronic signatures will be strictly confidential.  
The data will be subjected to consistency and validation checks within the EDC system. Completed eCRF images 
with the date-and-time stamped electronic audit trail indicating the user, the data entered, and any reason for 
change (if applicable) will be archived at the Investigator’s site and a backup copy archived with the CAVI-J office. 
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Primary data collection based on source-documented hospital and/or clinic chart reviews will be performed clearly 
and accurately by the clinical site personnel trained on the protocol and eCRF completion. eCRF data will be 
collected for all patients that are registered into the study. 
Record Retention. 
The sponsor will archive and retain all documents pertaining to the study for the time of the study under evaluation, 
and for lifetime during the post-study phase. The Investigator must obtain permission from Executive Steering 
Committee (ESC) in writing before destroying or transferring control of any study investigation records. 
Publication Policy.  
All publications and other public disclosures related to the Study shall be by the decision of the ESC, in cooperation 
with the study investigators and clinical site. All publications or other disclosures must be approved in advance by 
the ESC.  
Study investigators may use all study-related data for the purposes of scientific investigations, scientific abstracts, 
and scientific publications as has been approved by the ESC. 
The CAVI-J office will be responsible for registering the study on clinicaltrials.gov, or any other clinical 
investigations, in accordance with the International Committee of Medical Journal Editors guidelines, or any other 
applicable guidelines.  
12. STUDY ORGANIZATION
Study Investigators. 
The Investigator(s) undertake(s) to perform CAVI-J in accordance with this protocol, ICH guidelines for Good 
Clinical Practice and the applicable regulatory local requirements. 
The Investigator is required to ensure compliance with all procedures required by this protocol. The Investigator 
agrees to provide reliable data and all images into the EDC system in an accurate and timely fashion. The 
Investigator may appoint such other individuals as he/she may deem appropriate as Sub-Investigators to assist in 
the conduct of the study. All Sub-Investigators shall be appointed and listed. The Sub-Investigators will be 
supervised by and under the responsibility of the Investigator. The Investigator will provide them with a CAVI-J 
Protocol and all necessary information to successfully perform the study. 
Data Coordinating Center (DCC). 
As the DCC, CAVI-J office bears responsibility for monitoring interim data and analyzing the study's results in 
conjunction with the Investigators. Issues relating to regulatory reporting are the responsibility of both the 
Investigator and the DCC will aim to support these activities. The DCC will coordinate and monitor the study 
activities in alliance with the Principal Investigators, the ESC, and the sub-committees. 
Organizational and Leadership Design.  
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dedicated disease-specific sub-committees. 
Study Chairs. 
The Study Chair will be responsible for the overall leadership of the study. The Study Chairs will work with site 
investigators and subcommittees, and will be responsible for reporting any pertinent findings to the ESC. 
The Study Chair will be: 
Hajime Orimo, MD 
Principal Investigators. 
Principal Investigators will be from investigative sites. 
Executive Steering Committee. 
The ESC is charge with the responsibility for ensuring scientific quality and study fairness. It is composed of the 
Study Chair, Principal Investigators, and Site Investigators. The ESC will meet at once a year to review study 
progress and conduct. The ESC will provide feedback to the CAVI-J office and study investigators after each 
meeting and on an ad hoc basis. In that capacity, The ESC will address and resolve scientific issues encountered 
during the study. All final decisions regarding trial or protocol modifications rest with the ESC. 
All proposed research investigations for CAVI-J study must be approved by the ESC. 
The ESC membership will be comprised of the following (in alphabetical order): 
1. Shigeo Horinaka, MD
2. Kohji Shirai, MD
3. Hiroshi Ito, MD
4. Jitsuo Higaki, MD
Clinical Endpoint Review Committee 
The Clinical Endpoint Review Committee (CEC), consisting of members blinded to information about the patients, 
will assess the appropriateness of the clinical judgment of the cardiovascular events according to prespecified 
criteria. 
The CEC membership will be comprised of the following: 
1. Masanobu Takata, MD
2. Kuniaki Otsuka, MD
3. Shinichi Oikawa, MD
Statistical consulting 
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13. Quality Control and Assurance
Site Qualification.  
Each clinical center will be required to obtain ethics committee approval for the protocol and consent (and their 
revisions) in a timely fashion, to recruit patients, to collect data and enter it accurately in the EDC system, to 
faithfully follow the protocol and adhere to the standards of Good Clinical Practice (GCP). Each participating site 
contributing patient-level data to CAVI-J study should meet the following site requirements:   
• ability to organize data required for completion of CAVI-J case report form
• ability to perform de-identification of Protection Health Information (PHI) securely on-site in a manner in
keeping with local regulations
Investigator Profile.  
The following information will be collected for all investigators who participate in the study: CVs, contact 
information including address, telephone, and email, Conflict of Interest Statement and Financial Disclosure 
Certifications prior to initiation of enrollment.  
Qualifications and Training.   
Clinical investigators will be cardiology investigators with expertise in vascular function test including CAVI.  
All clinical site investigators and coordinators will be trained by the DCC in the specifics of the protocol during 
site initiation in advance of patient enrollment. In addition, the investigators and coordinators will undergo a 
separate training session to gain familiarity with the EDC system.  
Safety Monitoring. 
Study Investigators and their site designees will be responsible for monitoring safety data throughout the course 
of the study. 
Delegation of Authority and PI Oversight.  
Principal Investigators are responsible for all study activities at their sites. They may delegate study tasks to 
qualified staff members while continuing to oversee all study activities. The Delegation of Authority Log will list 
each staff member’s title and responsibilities for the study. The PI is responsible for careful review of each staff 
member’s qualifications. 
Site Approval.  
The following documents must be collected prior to site approval and opening to patient enrollment: 
• Signed Research and Data Use Study Agreement
• Signed Conflict of Interest Statements
• Completed Delegation of Authority Log
• Signed and dated CVs for all staff on Delegation of Authority Log
• Ethics committee approval for protocol, informed consent document
• Study-specific training documents
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Prior to enrolling a patient, representatives from the DCC will conduct a site initiation for all investigators, 
coordinators, and any other health care professionals who may be involved in the study. 
Patient Confidentiality. 
All patients’ records will be kept confidential. Study Investigators, CAVI-J representatives may review source 
documentation as necessary, but all unique patient and hospital identifiers will be removed from source 
documents which are sent to the CAVI-J office. The aggregate data from this study may be published as per 
publication policy documented in this Protocol; however, no data with patient identifiers will be published. 
14. Statistical Plan
Sample size 
Sample size calculations: The relative risk of cerebrovascular event in patients with CAVI>10 has been 
estimated to be 1.73 compared with patients with CAVI ≤10; thus, the study enrolled 2.5 times as many patients 
with CAVI ≤10 as patients with CAVI>10, [19] in whom the risk of cerebrovascular events is anticipated to be 
4.6% in 5 years [24]. From these data, the risks of cerebrovascular events in patients with CAVI ≤10 and 
CAVI>10 were anticipated to be 0.038 and 0.066 in 5 years, respectively. To detect this risk difference, the 
required sample size was calculated by Freedman’s method to be 810 for CAVI ≤10 and 2024 for CAVI >10 
groups with a two-sided alpha of 5%, 80% power and 20% dropout rate [25]. On the basis of these assumptions, 
a sample size of 3000 was chosen for this study. 
Analysis plan 
Data collection: categorical data will be presented as absolute numbers and percentages. Continuous data will be 
presented as mean ± standard deviation. Participants will be classified into several groups based on CAVI value. 
Baseline characteristics was compared among them. The effect of CAVI on each endpoint will be analyzed using 
the proportional hazard model. Incremental prognostic value was analyzed with likelihood ratio test, ROC (receiver 
operating characteristic) curve analysis, NRI (net reclassification improvement), and IDI (integrated discrimination 
improvement). The cutoff for CAVI against the incidence of cardiovascular events will be determined by ROC 
analysis. 
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Appendix: Definition of adverse events 
Primary Endpoint 1. Cardiovascular death
2. Nonfatal myocardial infarction
3. Nonfatal stroke
Secondary Endpoint 1. All cause death
2. Stable angina pectoris with revascularization
3. New incidence of peripheral arterial disease (arteriosclerosis obliterans)
4. Aortic aneurysm
5. Aortic dissection
6. Heart failure with hospitalization
7. Deterioration in renal function (dialysis or renal transplantation)
Cardiovascular death  
Cardiovascular death includes death resulting from an acute myocardial infarction (MI), sudden cardiac death, 
death due to heart failure (HF), death due to stroke, death due to cardiovascular (CV) procedures, death due to 
CV hemorrhage, and death due to other CV causes. 
1. Death due to Acute Myocardial Infarction refers to a death by any cardiovascular mechanism (e.g.,
arrhythmia, sudden death, heart failure, stroke, pulmonary embolus, peripheral arterial disease) ≤ 30 days1
after a MI related to the immediate consequences of the MI, such as progressive HF or recalcitrant
arrhythmia. There may be assessable mechanisms of cardiovascular death during this time period, but for
simplicity, if the cardiovascular death occurs ≤ 30 days of the MI, it will be considered a death due to
myocardial infarction. Acute MI should be verified to the extent possible by the diagnostic criteria outlined for
acute MI or by autopsy findings showing recent MI or recent coronary thrombosis. Death resulting from a
procedure to treat a MI (percutaneous coronary intervention (PCI), coronary artery bypass graft surgery
(CABG)), or to treat a complication resulting from MI, should also be considered death due to acute MI.
2. Sudden Cardiac Death refers to a death that occurs unexpectedly, not following an acute MI, and includes
the following deaths:
a. Death witnessed and occurring without new or worsening symptoms
b. Death witnessed within 60 minutes of the onset of new or worsening cardiac symptoms, unless the symptoms
suggest acute MI
c. Death witnessed and attributed to an identified arrhythmia (e.g., captured on an electrocardiographic (ECG)
recording, witnessed on a monitor, or unwitnessed but found on implantable cardioverter-defibrillator review)
d. Death after unsuccessful resuscitation from cardiac arrest
e. Death 30 days after successful resuscitation from cardiac arrest and without identification of a specific cardiac
or non-cardiac etiology
f. Unwitnessed death in a subject seen alive and clinically stable ≤ 24 hours prior to being found dead without
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clinical status preceding death should be provided, if available) 
General Considerations 
o Unless additional information suggests an alternate specific cause of death (e.g., Death due to Other
Cardiovascular Causes), if a patient is seen alive ≤ 24 hours of being found dead, sudden cardiac death 
(criterion 2f) should be recorded. For patients who were not observed alive within 24 hours of death, 
undetermined cause of death should be recorded (e.g., a subject found dead in bed, but who had not been 
seen by family for several days). 
3. Death due to Heart Failure refers to a death in association with clinically worsening symptoms and/or signs
of heart failure regardless of HF etiology (see Heart Failure Event Definition). Deaths due to heart failure can
have various etiologies, including single or recurrent myocardial infarctions (unless ≤30 days after an MI, see
definition for Death due to Acute MI above), ischemic or non-ischemic cardiomyopathy, hypertension, or
valvular disease.
4. Death due to Stroke refers to death after a stroke that is either a direct consequence of the stroke or a
complication of the stroke. Acute stroke should be verified to the extent possible by the diagnostic criteria
outlined for stroke (see Cerebrovascular Event Definition).
5. Death due to Cardiovascular Procedures refers to death caused by the immediate complications of a
cardiac procedure unless procedure is to treat a myocardial infarction.
6. Death due to Cardiovascular Hemorrhage refers to death related to hemorrhage such as a non-stroke
intracranial hemorrhage (see Cerebrovascular Event Definition), non-procedural or non-traumatic vascular
rupture (e.g., aortic aneurysm), or hemorrhage causing cardiac tamponade. 7. Death due to Other
Cardiovascular Causes refers to a CV death not included in the above categories but with a specific, known
cause (e.g., pulmonary embolism or peripheral arterial disease).
Non-CV death  
Non-CV death is defined as any death not covered by cardiac death or vascular death. The CEC will be asked to 
determine the most likely cause of non-CV death. Examples of non-CV death are pulmonary causes, renal 
causes, gastrointestinal causes, infection (including sepsis), non-infectious causes (e.g., systemic inflammatory 
response syndrome), malignancy (i.e., new malignancy, worsening of prior malignancy), hemorrhage (not 
intracranial), accidental/trauma, suicide, non-CV organ failure (e.g., hepatic failure) or non-CV surgery. 
Myocardial infarction (non-fatal) 
1. General Considerations
The term myocardial infarction (MI) should be used when there is evidence of myocardial necrosis in a clinical 
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• Evidence of myocardial necrosis (either changes in cardiac biomarkers or postmortem pathological
findings); and 
• Supporting information derived from the clinical presentation, electrocardiographic changes, or the
results of myocardial or coronary artery imaging 
The totality of the clinical, electrocardiographic, and cardiac biomarker information should be considered to 
determine whether or not a MI has occurred. Specifically, timing and trends in cardiac biomarkers and 
electrocardiographic information require careful analysis. The adjudication of MI should also take into account the 
clinical setting in which the event occurs. MI may be adjudicated for an event that has characteristics of a MI but 
which does not meet the strict definition because biomarker or electrocardiographic results are not available. 
The term acute myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical 
setting consistent with acute myocardial ischemia. 
Under these conditions any one of the following criteria meets the diagnosis for MI: 
• Detection of a rise and/or fall of cardiac biomarker values [preferably cardiac troponin (cTn)] with at least
one value above the 99th percentile upper reference limit (URL) and with at least one of the following:
• Symptoms of ischemia
• New or presumed new significant ST-segment-T wave (ST-T) changes or
new left bundle branch block (LBBB).
• Development of pathological Q waves in the ECG.
• Imaging evidence of new loss of viable myocardium or new regional wall
motion abnormality.
• Identification of an intracoronary thrombus by angiography or autopsy
2. Criteria for Myocardial Infarction
a. Clinical Presentation
The clinical presentation should be consistent with diagnosis of myocardial ischemia and infarction. Other findings 
that might support the diagnosis of MI should be taken into account because a number of conditions are associated 
with elevations in cardiac biomarkers (e.g., trauma, surgery, pacing, ablation, heart failure, hypertrophic 
cardiomyopathy, pulmonary embolism, severe pulmonary hypertension, stroke or subarachnoid hemorrhage, 
infiltrative and inflammatory disorders of cardiac muscle, drug toxicity, burns, critical illness, extreme exertion, and 
chronic kidney disease). Supporting information can also be considered from myocardial imaging and coronary 
imaging. The totality of the data may help differentiate acute MI from the background disease process. 
b. Biomarker Elevations
For cardiac biomarkers, laboratories should report an upper reference limit (URL). If the 99th percentile of the 
upper reference limit (URL) from the respective laboratory performing the assay is not available, then the URL for 
myocardial necrosis from the laboratory should be used. If the 99th percentile of the URL or the URL for myocardial 
necrosis is not available, the MI decision limit for the particular laboratory should be used as the URL. Laboratories 
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the laboratory performing the assay are preferred over the manufacturer’s listed reference limits in an assay’s 
instructions for use. In general, troponins are preferred. CK-MB should be used if troponins are not available, and 
total CK may be used in the absence of CK-MB and troponin.  
For MI subtypes, different biomarker elevations for CK, CK-MB, or troponin will be required. The specific criteria 
will be referenced to the URL. 
c. Electrocardiogram (ECG) Changes
Electrocardiographic changes can be used to support or confirm a diagnosis of MI. Supporting evidence may be 
ischemic changes and confirmatory information may be new Q waves. 
• ECG manifestations of acute myocardial ischemia (in absence of left ventricular hypertrophy (LVH) and left
bundle branch block (LBBB)):
o ST elevation
New ST elevation at the J point in two contiguous leads with the cut-points: ≥ 0.1 mV in all leads other than 
leads V2-V3 where the following cut-points apply: ≥ 0.2 mV in men ≥ 40 years (≥ 0.25 mV in men < 40 years) 
or ≥ 0.15 mV in women. 
o ST depression and T-wave changes New horizontal or down-sloping ST depression ≥ 0.05 mV in two
contiguous leads and/or new T inversion ≥ 0.1 mV in two contiguous leads with prominent R wave or R/S ratio 
> 1.
The above ECG criteria illustrate patterns consistent with myocardial ischemia. In patients with abnormal 
biomarkers, it is recognized that lesser ECG abnormalities may represent an ischemic response and may be 
accepted under the category of abnormal ECG findings. 
• Criteria for pathological Q-wave
o Any Q-wave in leads V2-V3 ≥ 0.02 seconds or QS complex in leads V2 and V3
o Q-wave ≥ 0.03 seconds and ≥ 0.1 mV deep or QS complex in leads I, II, aVL, aVF, or V4-V6 in any two
leads of a contiguous lead grouping (I, aVL; V1-V6; II, III, and aVF) 
• ECG changes associated with prior myocardial infarction
o Pathological Q-waves, as defined above
o R-wave ≥ 0.04 seconds in V1-V2 and R/S ≥ 1 with a concordant positive T wave in the absence of a
conduction defect 
• Criteria for prior myocardial infarction
Any one of the following criteria meets the diagnosis for prior MI:
o Pathological Q waves with or without symptoms in the absence of nonischemic causes
o Imaging evidence of a region of loss of viable myocardium that is thinned and fails to contract, in the absence
of a non-ischemic cause 
o Pathological findings of a prior myocardial infarction
Stroke (non-fatal) 
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cerebral hemorrhage with no apparent non-vascular cause (e.g., trauma, tumor, or infection). Available 
neuroimaging studies must be considered to support the clinical impression and to determine if there is a 
demonstrable lesion compatible with an acute stroke. Strokes will be classified as ischemic, hemorrhagic, or 
unknown. 
Diagnosis of stroke. For the diagnosis of stroke, the following four criteria should be fulfilled: 
• Rapid onset of a focal/global neurological deficit with at least one of the following:
– Change in level of consciousness
– Hemiplegia
– Hemiparesis
– Numbness or sensory loss affecting one side of the body
– Dysphasia/aphasia
– Hemianopia (loss of half of the field of vision of one or both eyes)
– Other new neurological sign(s)/symptom(s) consistent with stroke
Note: If the mode of onset is uncertain, a diagnosis of stroke may be made provided that there is no plausible 
non-stroke cause for the clinical presentation 
• Duration of a focal/global neurological deficit ≥24 hours OR <24 hours if attributable to at least one of the
following therapeutic interventions:
– Pharmacologic (i.e., thrombolytic drug administration)
– Non-pharmacologic (i.e., neurointerventional procedure such as intracranial angioplasty)
or 
– Available brain imaging clearly documents a new hemorrhage or infarct
or 
– The neurological deficit results in death
• No other readily identifiable non-stroke cause for the clinical presentation (e.g., brain tumor, trauma,
infection, hypoglycemia, peripheral lesion)
• Confirmation of the diagnosis by at least one of the following:
– Neurology or neurosurgical specialist
– Brain imaging procedure (at least one of the followings):
1 CT scan
2 MRI scan
3 Cerebral vessel angiography
– Lumbar puncture (i.e. spinal fluid analysis diagnostic of intracranial hemorrhage)
If a stroke is reported but evidence of confirmation of the diagnosis by the methods outlined above is absent, the 
event will be discussed at a full CEC meeting. In such cases, the event may be adjudicated as a stroke on the 
basis of the clinical presentation alone, but full CEC consensus will be mandatory. 
If the acute focal signs represent a worsening of a previous deficit, these signs must have either 
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or 
• Persisted for more than 24 hours and accompanied by an appropriate new CT or MRI finding
Classification of stroke. Strokes are sub-classified as follows: 
• Ischemic (non-hemorrhagic): A stroke caused by an arterial obstruction attributable to either a thrombotic
(e.g., large vessel disease/atherosclerotic or small vessel disease/lacunar) or embolic etiology. This
category includes ischemic stroke with hemorrhagic transformation (i.e. no evidence of hemorrhage on an
initial imaging study but appearance on a subsequent scan)
• Hemorrhagic: A stroke caused by a hemorrhage in the brain as documented by neuroimaging or autopsy.
This category will include strokes attributable to primary intracerebral hemorrhage (intraparenchymal or
intraventricular), subdural hematoma and primary subarachnoid hemorrhage
• Not assessable: The stroke type could not be determined by imaging or other means (e.g., lumbar puncture,
neurosurgery, or autopsy) or no imaging was performed.
Stable angina pectoris with coronary revascularization 
• Angina pectoris includes stable and unstable angina pectoris.
For diagnosis of unstable angina, the subject must first have had an episode of ischemic discomfort consistent 
with unstable angina (ischemic discomfort either at rest, of new onset, or in an accelerating pattern) lasting ≥10 
minutes, which occurred before the subject presented to the hospital. However, if an increase of biomarkers >5 × 
99th percentile URL (troponin or CK-MB >5 × 99th percentile URL) is observed, diagnosis will be myocardial 
infarction.  
• Coronary Revascularization
Attempted revascularization procedures, even if not successful, will be counted. Revascularization is divided by 
type and urgency. Planned revascularization is defined as ischemia-driven coronary revascularization (PCI or 
CABG). The evaluation of invasive or non-invasive functional ischemia is essential before PCI. Urgent 
revascularization is defined as coronary revascularization (PCI or CABG) that occurred during a hospitalization 
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New incidence of peripheral arterial disease (arteriosclerosis obliterans) 
Diagnosis of PAD. Follow the below work flow of TASC II (J Vasc Surg. 2007 Jan;45 Suppl S:S5-67.) 
The ankle–brachial index is a mandatory test. 
Aortic aneurysm 
Aneurysm is defined as a segmental, full-thickness dilation of a blood vessel that is 50 percent greater than the 
normal aortic diameter (> 30 mm in abdominal aorta and >45 mm in thoracic aorta). 
For diagnosis of aortic aneurysm, CT scan or MRI scan are mandatory. 
Aortic dissection 
Aortic dissection can result either from a tear in the intima and propagation of blood into the media or from 
intramural haemorrhage and haematoma formation in the media followed by perforation of intima; the former is 
more common. The characteristic picture of aortic dissection is the presence of an intimal flap in the aorta.  
CT scan with contrast image enhancement is required to identify the extent of the dissection along with the true 
and false lumens 
Classification of aortic dissection. DeBakey classification: 
• Type I involves ascending aorta, aortic arch, and descending aorta.
• Type II is confined to ascending aorta only.
• Type III is confined to descending aorta distal to the left subclavian artery only; IIIa extends up to diaphragm,
IIIb extends beyond the diaphragm.
Heart failure with hospitalization 
The date of this event will be the day of hospitalization of the patient including any overnight stay at an 
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following criteria:  
• Requires hospitalization defined as an admission to an inpatient unit or a visit to an emergency department
that results in at least a 12-hour stay (or a date change if the time of admission/discharge is not available)
• Clinical manifestations of heart failure (new or worsening), including at least one of the followings:
– Dyspnea
– Orthopnea
– Paroxysmal nocturnal dyspnea
– Edema
– Pulmonary basilar crackles
– Jugular venous distension
– Third heart sound or gallop rhythm
– Radiological evidence of worsening heart failure
• Additional/increased therapy: at least one of the followings:
– Initiation of oral diuretic, intravenous diuretic, inotrope, or vasodilator therapy
– Up-titration of oral diuretic or intravenous therapy, if already on therapy
– Initiation of mechanical or surgical intervention (mechanical circulatory support, heart transplantation, or
ventricular pacing to improve cardiac function); or the use of ultrafiltration, hemofiltration, or dialysis that is
specifically directed at the treatment of heart failure
Changes in a biomarker (e.g., brain natriuretic peptide) consistent with CHF will support this diagnosis. 
Requirement for Renal Replacement Therapy 
Definition of renal replacement therapy: 
• Kidney transplantation
Definitive renal replacement therapy prescribed when uremic symptoms have already occurred, or are
anticipated to occur, due to the progression of irreversible chronic kidney disease. Death during the transplant
surgery will be considered kidney transplantation.
• Chronic dialysis
ESKD will be diagnosed if dialysis is performed for 30 days or more and is not subsequently known to recover.
Indications for dialysis are indicated in section below.
Onset of ESKD 
The mode of onset of ESKD will be adjudicated into the following categories: 
• Chronic progression
• Acute deterioration, diagnosed when the decline in kidney function is sudden and acute kidney injury is
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Table S1. Characteristics of patients who completed and who failed to complete the study 
Characteristic 
Patients who completed 
n = 2932 
Patients who failed to complete 
n = 94 
p 
Age, mean (SD), y 63.2 (8.0) 61.3 (9.7) .014 
Male 2001 (68.3) 62 (66.0) .639 
Systolic blood pressure, mean (SD), mmHg 133.2 (16.5) 134.9 (20.1) .329 
Diastolic blood pressure, mean (SD), mmHg 80.0 (11.4) 80.0 (13.2) .979 
Diabetes mellitus 2209 (75.3) 66 0 (70.2) .275 
Metabolic syndrome 1395 (47.6) 58 (61.7) .007 
Hypertension categorized as high-risk 2431 (82.9) 62 (66.0) <.001 
Hypertension 2597 (88.6) 70 (74.5) .001 
Chronic kidney disease stage 3 1125 (38.4) 35 (37.2) .824 
History of coronary artery disease or cerebral infarction 1115 (38.0) 24 (25.5) .014 
Total cholesterol, mean (SD), 183.8 (34.6) 190.7 (38.1) .061 
HDL cholesterol, mean (SD), 55.0 (15.4) 54.3 (17.8) .704 
Obesity 359 (12.2) 12 (12.8) .879 
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Regular Exercise 1026 (37.2) 27 (31.8) .209 
Medications 
Anti-hypertensive agents 2260 (77.1) 52 (55.3) <.001 
Insulin 174 (6.0) 11 (12.1) .022 
Anti-diabetic agents 1109 (37.8) 39 (41.5) .471 
lipid-lowering agents 1805 (61.6) 42 (44.7) .001 
Antiplatelet agents 1092 (37.2) 20 (21.3) .002 
Data are presented as number (percentage) of participants unless otherwise indicated. 
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Table S2. Univariate cox regression analysis for the primary outcome 
Characteristic HR (95%CI) P 
Age (per year) 1.02 (1.00‒1.06) .065 
Male 3.38 (1.74‒6.54) <.001 
Systolic blood pressure (per mmHg) 1.01 (1.0‒1.02) .142 
Diastolic blood pressure (per mmHg) 1.00 (0.98‒1.01) .660 
Diabetes mellitus 1.12 (0.67-1.90) .659 
Hypertension 1.64 (0.71-3.76) .245 
Chronic kidney disease 1.29 (0.83-2.00) .251 
History of coronary artery disease or cerebral infarction 1.49 (0.97-2.30) .071 
Total cholesterol (per mg/dL) 1.00 (0.99-1.01) .766 
HDL cholesterol (per mg/dL) 0.97 (0.96-0.99) .002 
Obesity 0.88 (0.44-1.77) .729 
Smoking habits 1.80 (1.16-2.79) .009 
Regular Exercise 1.08 (0.69-1.69) .747 
Medications 
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Insulin 1.98 (0.99-3.95) .053 
Anti-diabetic agents 1.17 (0.75-1.81) .486 
lipid-lowering agents 0.88 (0.56-1.36) .554 
Antiplatelet agents 1.87 (1.21-2.88) .005 
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